PD-1

[Nature Communications] Investigators found that GATA4 promoted non-cell autonomous tumor suppression in multiple model systems. Mechanistically, they showed that Gata4-dependent tumor suppression required cytotoxic CD8 T cells and partially required the secreted chemokine CCL2.

[Merck] Merck announced that the Phase III KEYNOTE-091 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression.

[Frontiers in Immunology] Scientists examined the effect of selectively blocking the function of sCTLA-4 on in vitro immune responses from volunteer healthy or melanoma patient PBMC samples.

[NOXXON Pharma N.V.] NOXXON Pharma N.V. announced that the Data Safety Monitoring Board positively evaluated safety data from the initial four weeks of treatment of the first patient enrolled in the GLORIA clinical trial expansion arm.

[Hepatology] Scientists identified interferon regulatory factor (IRF8) as an important prognostic biomarker in hepatocellular carcinoma patients which predicted the response and sensitivity to anti-PD-1 therapy.

[Journal of Clinical Oncology] The authors report the current status of first-line immunotherapy in metastatic non–small cell lung cance together with current challenges in selecting the best immunotherapeutic approach for the individual patient.